The Relationship of Serum Hemojuvelin and Hepcidin Levels with Iron Overload in Nonalcoholic Fatty Liver Disease

Boğa, Salih; Alkım, Hüseyin; Alkım, Canan; Koksal, Ali Riza; Bayram, Mehmet; Özgüven, Banu Yılmaz; Neijmann, Şebnem Tekin

doi:10.15403/jgld.2014.1121.243.hak

Cited by 26 publications

(24 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most of the studies showed no signs of biochemical or histological iron overload to explain the higher ferritin levels. 2,27,36,37,45,48,49 Ferritin showed a significant positive correlation with lobular inflammation, 2,22,44 portal inflammation, 2,50 higher NAS, 22,44 severity of steatosis, 22,26,44,51 presence of fibrosis, 2,22,26,44,51 and presence of NASH 48 and ballooning. 22,44…”

Section: Hyperferritinemia Related To Inflammationmentioning

confidence: 93%

“…25 The regulators of iron homeostasis focusing on serum transferrin receptor-1 (TfR1), TfR2, divalent metal transporter-1 (DMT-1), ferroportin, hepcidin, and hemojuvelin were also studied in NAFLD patients, but results were inconsistent. 12,21,[23][24][25][34][35][36][37][38][39][40][41] No significant correlations were found between NAFLD patients (NASH and HS) compared with control subjects in duodenal or serum DMT-1 messenger ribonucleic acid (mRNA) levels, 23,39,41 TfR1 and 2 mRNA levels, 23,35,36,41 and serum, duodenal, and hepatic ferroportin concentration. 23,24,35,38,39,41 Increased hepcidin levels were found in three studies 23,35,39 measuring hepcidin in NAFLD patients (NASH and HS) compared with control subjects.…”

Section: Hfe Mutations and Iron Regulators In Nafldmentioning

confidence: 99%

“…An important upstream regulator of hepcidin expression is hemojuvelin. Two studies 23,37 investigating hemojuvelin found lower levels in NAFLD patients versus control subjects. Lower copper levels were associated with higher ferritin levels and increased prevalence of siderosis and hepatic iron in NAFLD patients.…”

Section: Hfe Mutations and Iron Regulators In Nafldmentioning

confidence: 99%

“…In addition to the standard inflammatory serum biomarkers measured in NAFLD patients, ferritin is often found to be significantly higher in NASH patients when compared with controls or patients with HS. 27,36,37,42,[45][46][47] In several of these studies, 37,38,45 serum iron parameters were also investigated; however, no significant difference in iron status was found between the groups.…”

Section: Hyperferritinemia Related To Inflammationmentioning

confidence: 99%

“…A wide range of indirect and direct inflammatory parameters were found to be significantly higher in NAFLD or NASH patients when compared with control subjects (e.g., aspartate aminotransferase, thioredoxin, C-reactive protein, α-2-macroglobulin, ceruloplasmin, malondialdehyde, hepatic 8-oxodG, nitric oxide, interleukin-6, interleukin-8, and tumor necrosis factor-α). Most studies also found ferritin levels to be significantly higher in NASH patients compared with control subjects and/or patients with HS and NAFLD patients compared with control subjects 27,36,37,42,[45][46][47][48][49] (►Supplementary Table S2 [online only]). Most of the studies showed no signs of biochemical or histological iron overload to explain the higher ferritin levels.…”

Section: Hyperferritinemia Related To Inflammationmentioning

confidence: 99%

See 4 more Smart Citations

Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation?

et al. 2019

View full text Add to dashboard Cite

Hyperferritinemia, observed in inflammation, iron overload as well as in combination of both, is found in ∼30% of nonalcoholic fatty liver disease (NAFLD) patients. The authors summarized the evidence regarding the potential cause of hyperferritinemia in NAFLD, as this may affect the indicated therapy. A systematic literature search was conducted in EMBASE, PubMed, MEDLINE, and the Cochrane library. In the majority of NAFLD patients, hyperferritinemia is due to inflammation without hepatic iron overload. In a smaller group, a dysmetabolic iron overload syndrome (DIOS) is found, showing hyperferritinemia in combination with mild iron accumulation in the reticuloendothelial cells. The smallest group consists of NAFLD patients with hemochromatosis. Phlebotomy is only effective with hepatocellular iron overload and should not be the treatment when hyperferritinemia is related to inflammation, whether or not combined with DIOS. Treatment with lifestyle changes is to date probably the more effective way until new medication is becoming available.

show abstract

Section: Hyperferritinemia Related To Inflammationmentioning

confidence: 93%

Section: Hfe Mutations and Iron Regulators In Nafldmentioning

confidence: 99%

Section: Hfe Mutations and Iron Regulators In Nafldmentioning

confidence: 99%

Section: Hyperferritinemia Related To Inflammationmentioning

confidence: 99%

Section: Hyperferritinemia Related To Inflammationmentioning

confidence: 99%

See 3 more Smart Citations

Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation?

et al. 2019

View full text Add to dashboard Cite

show abstract

Hepatic STAMP2 alleviates polychlorinated biphenyl‐induced steatosis and hepatic iron overload in NAFLD models

Kim

Park

et al. 2022

Environmental Toxicology

View full text Add to dashboard Cite

Polychlorinated biphenyls (PCBs) have been associated with neurotoxicity, hepatoxicity, oncogenicity, and endocrine-disrupting effects. Although the recent studies have demonstrated that PCB exposure leads to nonalcoholic fatty liver disease (NAFLD), the underlying mechanism has remained unsolved. In this study, we examined the hepatic effects of a PCB mixture, Aroclor 1260, whose composition mimics human bioaccumulation patterns, and PCB 126 in C57BL/6 mice. Male C57Bl/6 mice were fed a standard diet or a 60% high-fat diet and exposed to Aroclor 1260 (10 mg/kg or 20 mg/kg) or PCB 126 (1 mg/kg or 5 mg/kg) by intraperitoneal injection for a total of four injections (2, 3, 4, and 5 weeks) for 6 weeks. In mice, both Aroclor 1260 and PCB 126-induced liver damage, hepatic steatosis and inflammation. We also observed that PCB exposure-induced hepatic iron overload (HIO). We previously demonstrated that hepatic six transmembrane protein of prostate 2 (STAMP2) may represent a suitable therapeutic target for NAFLD patients. Thus, we further examined whether hepatic STAMP2 is involved in PCB-induced NAFLD. We observed that hepatic STAMP2 was significantly decreased in PCB-induced NAFLD models in vivo and in vitro. Furthermore, overexpression of hepatic STAMP2 using an adenoviral delivery system resulted in improvement of PCB-induced steatosis and HIO in vivo and in vitro. Our findings indicate that enhancing hepatic STAMP2 expression represents a potential therapeutic avenue for the treatment of PCB exposure-induced NAFLD.

show abstract

Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets

Guo

Liu

et al. 2022

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

The Relationship of Serum Hemojuvelin and Hepcidin Levels with Iron Overload in Nonalcoholic Fatty Liver Disease

Cited by 26 publications

References 30 publications

Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation?

Hyperferritinemia in Nonalcoholic Fatty Liver Disease: Iron Accumulation or Inflammation?

Hepatic STAMP2 alleviates polychlorinated biphenyl‐induced steatosis and hepatic iron overload in NAFLD models

Iron overload in alcoholic liver disease: underlying mechanisms, detrimental effects, and potential therapeutic targets

Contact Info

Product

Resources

About